Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy–Suppressed Viral Load

Journal:

Journal of Infectious Diseases

Published:

2026-04-07

DOI:

10.1093/infdis/jiag142

Affiliations:

5

Authors:

10

Go to article

Institutions	Authors	Share
AbbVie, United States of America (USA)	6.000000	0.60
Quest Clinical Research, United States of America (USA)	1.000000	0.10
North Texas Infectious Diseases Consultants (NTIDC), United States of America (USA)	1.000000	0.10
Central Texas Clinical Research, United States of America (USA)	1.000000	0.10
Ruane Clinical Research Group Inc., United States of America (USA)	1.000000	0.10

Interested in Oncology and Carcinogenesis?